Advanced Topics

Advanced Topics

Explore advanced topics around weight loss injections, including plateaus, switching treatments, and stopping safely.

Whether you have been on Mounjaro or Wegovy for several months and are running into specific scenarios — plateau, dose questions, switching between medicines, or thinking about stopping — this is the advanced topics hub for ongoing weight-loss-injection treatment in the UK. Each section below summarises a topic and links to a deeper guide. LetsLoseWeight is an independent comparison site; we do not prescribe medication, and any decision about your treatment should be discussed with your prescriber.

Plateaus — when the scale stops moving

Most patients hit a plateau at some point. Short plateaus (2–4 weeks) are normal and usually resolve on their own. Medium plateaus (4–8 weeks) often have an addressable cause — a higher dose, adherence, calorie intake, other medicines, or untreated comorbidities. Long plateaus (8+ weeks) are worth a formal review with your prescriber.

The single most common reason for a plateau: not being on the maximum tolerable dose.

For full detail, including which factors to audit and what each plateau length should prompt, see our plateau and not losing weight guide.

Switching from Wegovy to Mounjaro

Common reasons to switch: plateau on Wegovy 2.4mg, side-effect tolerance, or wanting to try a medicine with greater average weight loss (the SURMOUNT-5 head-to-head trial in 2025 favoured tirzepatide).

The standard approach: stop Wegovy, wait around 5 weeks for semaglutide to clear, start Mounjaro at the standard 2.5mg starter dose regardless of where you were on Wegovy, then follow the standard Mounjaro titration. The starter dose can't be skipped because the GIP-receptor activation in Mounjaro is something your body has not yet been exposed to.

For practical detail, including expectations during the washout and after restart, see our switching from Wegovy to Mounjaro guide.

Switching to retatrutide — why you can't yet

Retatrutide is not licensed in the UK at the time of this guide. No GPhC-registered UK pharmacy can supply it, and there is no legitimate switching pathway. The only legitimate way to access retatrutide in the UK is through a registered clinical trial.

If you are unhappy with progress on Mounjaro or Wegovy, the realistic options are: optimise current treatment (dose, adherence, lifestyle), switch between Mounjaro and Wegovy, take part in a clinical trial, or wait for MHRA approval.

For full detail, see our switching to retatrutide guide.

Stopping safely

Stopping is not medically dangerous in itself — Mounjaro and Wegovy are not addictive and do not cause withdrawal symptoms. The realistic outcome is gradual weight regain over 12–18 months. The licensed approach does not require tapering, but some prescribers recommend a step-down for practical reasons.

The factors that improve outcomes after stopping include continued lifestyle changes, especially physical activity and protein intake, and active self-monitoring.

For practical detail including the NHS Wegovy 2-year cap, see our stopping injections safely guide.

What happens when you stop — the long-term picture

The most-cited evidence on post-stopping outcomes is the STEP 1 trial extension, which followed participants for 12 months after stopping semaglutide and found, on average, around two-thirds of lost weight regained. Cardiometabolic improvements (blood pressure, blood sugar, lipids) tend to reverse on a similar timeline.

This is consistent with obesity behaving like a chronic condition rather than a time-limited problem. Treatment is increasingly framed as long-term — analogous to medicines for blood pressure or cholesterol — rather than a short course.

For full detail, see our what happens when you stop guide.

Restarting after a break

After a gap of more than 2–4 weeks, you cannot simply pick up at your previous dose. Tolerance fades, and resuming at the same dose can produce nausea and gastrointestinal upset comparable to your first weeks on the medicine. The standard approach is to drop back at least one dose level and re-titrate; for gaps over 4 weeks, restart from the starter dose.

For full detail, see our restarting weight loss injections guide.

What affects individual results

Trial averages compress a wide spread of outcomes. Around 9–14% of trial participants did not lose 5% even at the highest doses; a similar proportion lost more than 25%. Factors that shift the curve include:

  • Within your control: adherence, calorie intake, protein, activity, sleep, alcohol
  • Partially within control: tolerated dose, other medicines that promote weight gain, stress
  • Outside your control: starting weight, individual biology, age, sex, underlying conditions

For full detail, see our what affects results guide.

Long-term continuation

Increasingly, the treatment plan extends beyond the original trial duration of 68–72 weeks. NICE TA875 caps NHS Wegovy at 2 years. NICE TA1026 does not cap NHS Mounjaro. Private treatment has no fixed time limit. The realistic expectation for many patients is long-term treatment, with periodic clinical review of whether continuation remains appropriate.

For more on routes and continuation options, see our private vs NHS guide.

Drug interactions to flag long-term

Most medicines have no interaction with Mounjaro or Wegovy. Specific points worth flagging if anything in your other medications changes:

  • Oral contraceptives — Mounjaro specifically warns about reduced absorption; non-oral methods or barrier additions for 4 weeks after each dose increase
  • Insulin and sulfonylureas in type 2 diabetes — risk of hypoglycaemia, may need adjustment
  • New medications that promote weight gain (some antidepressants, antipsychotics, steroids)

For the full eligibility and interaction picture, see our eligibility guide.

Pregnancy and family planning

Both Mounjaro and Wegovy are not licensed in pregnancy or during breastfeeding. The licensed advice is to stop:

  • Mounjaro: at least one month before a planned pregnancy
  • Wegovy: at least two months before a planned pregnancy (semaglutide has a longer half-life)

Anyone who becomes pregnant while taking either medicine should stop and contact their prescriber.

Long-term safety monitoring

Both medicines carry a black triangle (▼) in the BNF and patient information leaflet, indicating they are under additional safety monitoring. Patients are encouraged to report any suspected side effect, however minor, through the MHRA Yellow Card scheme.

For long-term safety detail, see our safety and side effects hub.

Frequently asked questions

How long can I stay on these medicines?
There is no fixed limit on private treatment. NHS Wegovy is capped at 2 years; NHS Mounjaro is not. Long-term continuation is common where treatment remains clinically appropriate.

Should I switch from Wegovy to Mounjaro?
Generally only worth considering if you've reached the maximum tolerated Wegovy dose without satisfactory progress, or if you have specific reasons (cost, supply, side effects). Switching always involves transition costs.

Will I always need to take this?
For most patients with obesity, treatment is most effective when continued long-term. Stopping leads to regain on average. Some patients maintain successfully without medication after intensive treatment, but they are the minority.

Can I take a planned break to "reset"?
Stopping does not "reset" the body's response to the medicine in any way that improves outcomes. Stop-restart cycles tend to produce worse outcomes than continuous treatment.

Is the medicine still effective after several years?
The evidence to date suggests yes. The longest published trials run to several years and show maintained weight loss. Real-world long-term data is gradually accumulating.

Next steps

Use the links above to dive into a specific topic, or:

Sources

This guide is for general information only and is not a substitute for professional medical advice. Decisions about your specific treatment should be made with your prescriber.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
Advanced Topics: Mounjaro & Wegovy UK Hub | LetsLoseWeight